knowledge -WSS

knowledge

author：comprehensive 2025-10-02 12:31:46 - browse：34184

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Beyond aggravation: Constipation is an American epidemic

WSS

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Brain worms: The science behind RFK Jr.'s parasitic infection

Making AI in medicine accessible to smaller, and rural hospitals

Study: AI not yet building 'n

New research sheds light on how often breast cancer is overdiagnosed

Decentralized clinical trials need collaboration to achieve wider use

knowledge

knowledge

focus

Virginia high school admissions case could be legal follow

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Peter Hotez and the public health issue of online harassment

Study: Adult vaccinations pay for themselves in societal benefits

Dobbs anniversary: the lost opportunity of abortion as health care

U.S. death rates show how politics are affecting public health

Alkermes shareholders re

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Medical records are filled with copy

The world needs the new pandemic treaty

Wikipedia

Sanofi strikes deal with Novavax, boosting the vaccine maker

Steward Health Care files for bankruptcy

How to improve immunocompromised access to mAb treatments

Congress: Prevent baby formula shortages by passing a new bill

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Readout LOUD podcast: What to know about H5N1 bird flu

knowledge

knowledge

focus

explore